EXPRESS MAIL NO. EV336618218US

Sheet 1 of 2

FORM PTO-1449 (REV.7-80)	U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	ATTY. DOCKET NO. 480140.442C1	APPLICATION NO. 09/765,105
	INFORMATION DISCLOSURE STATEMENT (Use several sheets if necessary)	APPLICANTS Donald S. Karanewsky et al.	
		FILING DATE January 16, 2001	GROUP ART UNIT 1653

OIPE JC54 OCT 27 2003 PATENT & TRADEMARK OFFICE

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
DL	AA	6,235,899	05/22/01	Bouchet et al.	540	500	
	AB						
	AC						
	AD						

FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	COUNTRY	TRANSLATION YES	TRANSLATION NO
DL	AE	WO 97/22619	06/26/97	WIPO		
	AF	WO 98/10778	03/19/98	WIPO		
	AG	WO 99/03852	01/28/99	WIPO (+ English Translation)	X	
	AH	WO 00/01666	01/13/00	WIPO		
	AI	WO 00/23421	04/27/00	WIPO		
	AJ	WO 01/00658	01/04/01	WIPO		
	AK	WO 01/51462	07/19/01	WIPO		
DL	AL	WO 01/81330	11/01/01	WIPO		

OTHER PRIOR ART *(Including Author, Title, Date, Pertinent Pages, Etc.)*

DL	AM		Chapman K., "Synthesis of a Potent, Reversible Inhibitor of Interleukin-1β Converting Enzyme," *Bioorganic & Medicinal Chemistry Letters 2*(6):613-618, 1992.
DL	AN		Cheung et al., "Synthesis of 3-Amino-3-Vinylpropanoic Acid and its Conversion to 4-Amino-5-Hydroxy-4,5-Dihydrofuran-2-one Hydrochloride (HAD), A Cyclic Stabilised Form of Aspartate 1-Semialdehyde Hydrocholride," *Tetrahedron 53*(46):15807-15812, 1997.
DL	AO		de Lange et al., "Asymmetric 1, 4-Additions to 5-Alkoxy-2(5H)-Furanones Enantioselective Synthesis and Absolute Configuration Determination of β-Amino-γ-Butyrolactones and Amino Diols," *Tetrahedron 45*(21):6799-6818, 1989.

EXAMINER	David Lukton	DATE CONSIDERED	02-05-04

* EXAMINER: Initial if reference considered, whether or not criteria is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant(s).

EXPRESS MAIL NO. EV336618218US

FORM PTO-1449 (REV.7-80)	U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	ATTY. DOCKET NO. 480140.442C1	APPLICATION NO. 09/765,105
		APPLICANTS Donald S. Karanewsky et al.	
	INFORMATION DISCLOSURE STATEMENT (Use several sheets if necessary)	FILING DATE January 16, 2001	GROUP ART UNIT 1653

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	BA						
	BB						
	BC						
	BD						

FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	COUNTRY	TRANSLATION YES	TRANSLATION NO
	BE					
	BF					
	BG					

OTHER PRIOR ART *(Including Author, Title, Date, Pertinent Pages, Etc.)*

DR	BH		Faber et al., "Catalytic Kinetic Resolution of 5-Alkoxy-2(5H)-Furanones," *Tetrahedron 50*(16):4775-4794, 1994.
	BI		Feringa et al., "Asymmetric Synthesis of 2-Amino-1, 4-Diols," *Tetrahedron Letters 29*(11):1303-1306, 1988.
	BJ		Feringa et al., "1, 4-Additions of Amines to 5-Methoxyfuran-2(5H)-One; An Efficient Synthesis of Amino Diols," *Heterocycles 27*(5):1197-1205, 1988.
	BK		Furuichi et al., "Common Synthetic Strategy for Optically Active Cyclic Terpenoids having a 1,1,5-Trimethyl-*Trans*–Decalin Nucleus: Syntheses of (+)-Acuminolide, (-)-Spongianolide A, and (+)-Scalarenedial," *Tetrahedron 57*, pp. 8425-8442, 2001.
	BL		Gonzalez et al., "Pseudoesters and Derivatives. Part38.[1] 1,3-Dipolar Cycloadditions of Aryl Azides and an Aziridine, *Via* Azomethine Ylide, to 2(5H)-Furanones Substituted at the 5-Position by Methoxy and Sulfur Bearing Groups," *Heterocycles 52*(1):237-251, 2000.
	BM		Leblanc et al., "Sar in the Alkoxy Lactone Series: The Discovery of DFP, A Potent and Orally Active Cox-2 Inhibitor," *Bioorganic & Medicinal Chemistry Letters 9*, pp. 2207-2212, 1999.
DR	BN		Lubben et al., "Asymmetric Synthesis of β-Lactams via Amine Additions to 5(R)-Menthyloxy-2[5H]-Furanone," *Tetrahedron: Asymmetry 2*(8):775-778, 1991.

EXAMINER David Lutton	DATE CONSIDERED 02-04-04

* EXAMINER: Initial if reference considered, whether or not criteria is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant(s).